Lifespan by David Sinclair — From the Lab to the Bookshelf

The big idea: ageing as lost information

Published by Atria Books in the US and Thorsons in the UK, Lifespan runs to 310 pages in three parts: the past, the present and the future of ageing research. It opens with the recognised hallmarks of ageing, from DNA damage to stem-cell exhaustion. Then it builds towards Sinclair's own theory.

The epigenome: a manual with coffee stains

Every cell carries the same DNA. What makes a kidney cell different from a nerve cell is the epigenome: chemical marks that switch genes on or off. Sinclair argues that stress and DNA breaks gradually scramble these marks. Lifespan.io offers a vivid image: an instruction manual with pages torn out and coffee spilt over them.

In Scott Alexander's retelling, an ageing kidney cell becomes "mostly kidney" but slightly confused about its identity. He also highlights the book's most striking clue. A clone of a 70-year-old starts life at zero years old, so DNA damage alone cannot be the whole story.

Sirtuins: the cellular repair crew

In the book, sirtuins are the repair crew that keeps epigenetic marks in place. Sinclair describes a "survival circuit": mild stressors such as fasting, exercise or cold activate sirtuins and cellular defences. Outside magazine notes that this circuit has yet to be proven in a trial setting. We explore the wider theory in our article on the secrets of ageing according to David Sinclair.

His most ambitious hypothesis goes further still. He proposes that cells keep a "backup copy" of their youthful epigenetic state. By his own account, where this information is stored is not yet known.

Why NAD+ matters: the cell's working currency

If sirtuins are the repair crew, NAD+ is their wage. Nicotinamide adenine dinucleotide is the molecule that powers the machinery of our cells and helps build and maintain their structures. Mitochondria, the cell's power plants, depend on it to turn food into usable energy. Sirtuins consume it every time they work.

A decline observed in research

In the book, Sinclair states that we have roughly half as much NAD+ at 50 as at 20, as Outside summarised. Researchers from opposing camps agree that the NAD+ system comes under strain with age. Even Charles Brenner, a prominent critic of the book, describes damage that gradually reduces NAD+ over time. For the biology in more depth, see our guide to what NAD+ is and why cells need it.

NMN: one step from NAD+

Nicotinamide mononucleotide (NMN) is a direct NAD+ precursor found in every living cell. How it enters cells is still debated. Shin-ichiro Imai's group reported very fast uptake of NMN into cells, while Brenner argues that nicotinamide riboside (NR) is the better precursor.

What science says about NMN today

Blood NAD+: a consistent human finding

The clearest result is also the most basic. Across small human trials, NMN reliably raises blood NAD+ and was well tolerated. A review of 15 small trials found no extra side effects over periods of up to 24 weeks. Pooled together, however, those trials had not yet shown a clear metabolic benefit.

Yoshino et al., Science, 2021: a promising signal

The best-known efficacy study is Yoshino et al., Science 372, 1224–1229 (2021). It was the first clinical trial of NMN in humans, led by Imai's team. Postmenopausal women with prediabetes and overweight took 250 mg of NMN daily for 10 weeks. Their muscles became more sensitive to insulin Human, small.

Context matters. Other expected changes, such as better blood lipids, did not appear. Nautilus also notes that researchers on both sides of the NAD+ debate have commercial ties. Brenner advises an NR company, and Sinclair co-founded an NMN drug developer.

"It's some evidence in the right direction, but not compelling evidence that it's clinically therapeutic." — Samuel Klein, Washington University in St. Louis, in Nautilus

An open frontier

No trial has yet shown that NMN adds healthy years in humans. Lifespan extension remains an animal finding. Sinclair and Brenner agree on one thing: the field needs studies directly comparing NMN and NR. Larger, longer human trials are the next step, and that is what makes this field so exciting to follow.

A European milestone for NMN

Under EU Regulation 2015/2283, any food not widely eaten in the EU before May 1997 is a "novel food". It needs authorisation before it can be sold. NMN is the first NAD+ precursor of its kind to complete the full scientific review.

The timeline

What EFSA actually assessed

EFSA's 2026 opinion covers chemically synthesised β-NMN used in food supplements as a source of niacin. It concludes that up to 300 mg/day is safe for adults, excluding pregnant and lactating women. That dose provides about 109.7 mg of nicotinamide, well below the 900 mg/day upper level.

Two further details matter. The draft text grants the applicant five years of data protection once the regulation enters into force. Across the Atlantic, the FDA confirmed in a response letter of 29 September 2025 that NMN may again be sold as a US dietary supplement.

Reading Lifespan in 2026

The critics, read respectfully

Charles Brenner's review in Archives of Gerontology and Geriatrics argues that sirtuins do not extend lifespan across species. He also contends that resveratrol distorts the assay used to measure sirtuin activity. Sinclair responds that dozens of papers show the benefits of raising NAD+ are lost when sirtuins are deleted.

Nobel laureate Venki Ramakrishnan notes there is no evidence that resveratrol, NMN or metformin increase human lifespan. He remains hopeful that research is deepening our understanding of ageing. Fight Aging! calls Sinclair a self-promoter but credits his publicity with helping attract major investment into in vivo reprogramming. His friend Steven Austad summed up the paradox: Sinclair is "a superb scientist, as well as a superb salesman."

Sinclair's personal regimen: description, not prescription

The Sydney Morning Herald reports that Sinclair takes resveratrol, NMN and metformin daily, plus vitamins D and K2. He has said he is not recommending that anyone copy him. We share that caution. His regimen is a personal choice, not guidance.

Lifespan II and why the original still matters

Sinclair has announced a sequel: "Lifespan is the textbook, Lifespan II is the guidebook." Lifespan.io calls the first volume "a great entry-level book". Kirkus Reviews described it as "an uplifting review of the science".

Outside judged it dense but "worth your time". Even SkeptVet, which flags its exuberance, still recommends reading it critically. Reader discussions continue on Goodreads.

If you would like a more personal take before opening the book, read our book review of Lifespan from a passionate reader. It covers the chapters that stay with you, the ideas worth debating, and how to get the most from your own reading.

Conclusion: a book worth opening, a field worth following

Three things stand out. First, Lifespan by David Sinclair remains a vivid gateway into geroscience, even where its theories are contested. Second, NMN reliably raises blood NAD+ in humans, while broader benefits await larger, longer trials. Third, Europe has reached a genuine milestone: β-NMN was judged safe at 300 mg/day, and all 27 Member States backed its authorisation.

We recommend the book warmly: read it, question it, and keep following the studies. Curiosity is the best companion to any longevity science.

Please speak to a healthcare professional before starting any new supplement.

Frequently asked questions